The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Romidepsin and azacitidine in patients with R/R T-cell lymphoma
Matko Kalac, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, shares some updates from a retrospective analysis investigating the use of romidepsin and azacitidine in patients with relapsed/refractory (R/R) T-cell lymphoma. Dr Kalac first comments on the need to improve treatment options for patients with this disease and then discusses the safety and tolerability of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research: Johnson & Johnson
